What did @myjourney_lifelately actually say?
She missed her 5mg tirzepatide dose for a week because she hadn't reordered in time, then took 5mg the following week and spent the day feeling severely nauseous. Her read on it: "I don't know if it's because I've missed a week and then took 5 milligrams and that's just like for me being like well too much." She also noted that sipping water was the only thing offering any relief, and she was hoping the nausea would pass by the next morning so she could return to work.
This is a pretty common experience report from the Mounjaro community, and she's being honest about her uncertainty rather than presenting a confident medical theory. She doesn't tell anyone what to do. She's just documenting a rough day.
Does the science back this up?
Yes, and more specifically than she probably realises. The nausea after a missed dose followed by resumption is a real and documented phenomenon, not just bad luck.
Tirzepatide works partly by slowing gastric emptying and acting on GLP-1 and GIP receptors in the gut and brain. When you go a week without it, your GI system loses some of the adaptation it had built up. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed that GI side effects were most pronounced during dose escalation phases, precisely because the body hadn't yet adjusted. A one-week gap followed by a full dose effectively recreates that escalation scenario in miniature.
There's no published trial specifically on re-dosing after a one-week gap, but the pharmacokinetic half-life of tirzepatide is approximately five days (Eli Lilly prescribing information). After seven days, plasma levels are meaningfully lower than steady state. Jumping back to 5mg without stepping back down is biologically similar to escalating too fast.
What did they get wrong (or right)?
She got the core intuition right. Her theory, "I've missed a week and then took 5 milligrams and that's just like for me being like well too much," is actually a reasonable mechanistic hypothesis, not just post-hoc rationalisation.
What she didn't mention, and this is worth flagging, is that the standard clinical guidance from Eli Lilly and most prescribing frameworks in the UK is to restart at a lower dose after a gap of more than two weeks. She was just under that threshold at one week, but the pharmacokinetics suggest even a seven-day gap can reduce tolerance enough to matter, particularly in people who are GI-sensitive.
She didn't give any medical advice, didn't recommend her dose to others, and didn't make any claims about weight loss or cures. Credit where it's due: this is a personal experience update, and she frames it as exactly that throughout.
What should you actually know?
If you're on tirzepatide and you miss a dose, the approach matters. According to the UK Summary of Product Characteristics for Mounjaro, if more than four days have passed since your scheduled dose day, skip that dose and resume on your next scheduled day. If you've been off it for more than two weeks, stepping back down in dose is recommended before re-escalating.
Nausea from GLP-1 and GIP receptor agonists is primarily driven by delayed gastric emptying and central nervous system receptor activation. The Dahl et al. (2023, Obesity Reviews) systematic review found that nausea occurred in 18 to 24 percent of tirzepatide users at the 5mg dose, with rates highest during escalation. Eating smaller meals, avoiding fatty or spicy food around injection time, and staying hydrated (she got this right with the water sipping) are the interventions with the most practical support.
If nausea is severe, persistent beyond 48 hours, or accompanied by vomiting that prevents hydration, that warrants contact with a prescriber, not just waiting it out.